HRS-6093

· Jiangsu HengRui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HRS-6093, covering 2025-12-05 to 2025-12-05. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations [Phase 1]